Hypoglycaemia: difference between revisions
Diff·revision 8 → 9·01:00, 20 Dec 2024
Difference between revision 8 and revision 9 of Hypoglycaemia. 6 lines changed; the page grew by 143 bytes.
| Revision 8 — 07:33, 28 Nov 2024 ChainCustodyChad (talk) add the contraindication with its rationale 3,334 bytes +844 | Revision 9 — 01:00, 20 Dec 2024 OrphanPageOrin (talk) rm the comparison with a compound that has no comparable safety dataset 3,477 bytes +143 | ||
|---|---|---|---|
| 37 | <ref name="seaquist2013">Seaquist ER, Anderson J, Childs B, et al. "Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society." ''Diabetes Care'' 36(5):1384–1395 (2013). PMID 23589542.</ref> | 37 | <ref name="seaquist2013">Seaquist ER, Anderson J, Childs B, et al. "Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society." ''Diabetes Care'' 36(5):1384–1395 (2013). PMID 23589542.</ref> |
| 38 | 38 | ||
| + | 39 | == See also == | |
| + | 40 | * [[Insulin secretion]] | |
| + | 41 | * [[Beta cell function]] | |
| + | 42 | * [[GLP-1 receptor agonist]] | |
| + | 43 | * [[Adverse effects of GLP-1 receptor agonists]] | |
| + | 44 | ||
| 39 | {{DEFAULTSORT:Hypoglycaemia}} | 45 | {{DEFAULTSORT:Hypoglycaemia}} |
| 40 | [[Category:Adverse effects]] | 46 | [[Category:Adverse effects]] |